Figure 5From: Anti-erbB2 treatment induces cardiotoxicity by interfering with cell survival pathwaysTUNEL assay, 24 hours after addition of B-10 or doxorubicin. The first row shows untreated control cells. The second row shows doxorubicin (10 μmol/l) treated positive control cells. The third row shows B-10 treated cells. TUNEL, terminal uridine nick-end labeling.Back to article page